Shots:
- Natera has reported the commercial launch of Zenith genomics, a next-generation whole genome sequencing (WGS) assay designed to enhance the detection of rare diseases in the US
- The platform combines whole genome sequencing with long-read sequencing confirmation to detect genomic features such as tandem repeat expansions, supporting diagnosis of rare & ultra-rare conditions, & enabling improved clinical management
- The underlying tech for Zenith genomics was developed by MyOme, & through an exclusive partnership with Natera, will deliver the assay to US healthcare providers, with data presented at the ACMG Annual Clinical Genetics Meeting 2026
Ref: Businesswire | Image: Natera | Press Release
Related News: Natera Seeks US FDA Approval for Signatera Cdx To Support MRD-Guided Treatment in Bladder Cancer
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
